Informed Genomics

17/05/2024

During May, which is awareness month, we have been speaking to consultant urologists about the need for accessible and non-invasive testing solutions. Here's what Chris Blick has to say about our GALEAS™ Bladder cancer testing service and the potential benefits it offers to healthcare providers and patients. Read what other urologists say https://hubs.ly/Q02xxhbZ0

12/04/2024

We’re been nominated for a ‘Delivering Innovation into Health and Care’ award by Medilink Midlands, thanks to our collaborations with the NHS including our role as the only private lab supporting the NHS Jewish BRCA Testing Programme. These awards are designed to recognise and celebrate the best of innovation, collaboration and connectivity in the healthcare sector. We're looking forward to the awards ceremony on 9th May.

11/04/2024

A recent article in The Telegraph hailed GALEAS™ Bladder as a breakthrough in diagnostics, that could make it easier to detect bladder cancer early. Developed by our sister company Nonacus, the GALEAS™ test forms part of our complete bladder cancer DNA testing service to help clinicians detect the disease at every step. You can read more here https://bit.ly/3VZRRiV but if you don't have a subscription, the full article is also available on our website https://bit.ly/3JeVhGL

Knowing what signs to look out for is crucial in the fight to prevent cases of this disease becoming life-limiting

14/12/2023

Our new GALEAS™ Bladder test detects bladder cancer by picking up genetic markers in urine samples, which patients can provide from the comfort of their own home.

Of all patients currently referred for cystoscopy, only 10 per cent are diagnosed with bladder cancer. The GALEAS™ Bladder test could move the 90 percent of patients without cancer to a non-urgent pathway, freeing up resource for patients to undergo cystoscopies faster to confirm their cancer diagnoses.

From our recent launch, Chris Blick commented on our collaboration with BUPA, which makes the test available in the UK for the first time.

“It is incredibly exciting to see the successful transition from bench to bedside of a novel, non-invasive biomarker with high diagnostic accuracy. This test has the potential to alter the way patients are investigated and managed during their bladder cancer journey.”

Mr Chris Blick, Consultant Urologist at the Royal Berkshire Hospital

27/11/2023

Patients are our priority, and we strive to provide the right testing that has a meaningful impact on their experience and outcomes. We were delighted to see the support from the patient community when we announced our collaboration with Bupa to make our GALEAS™ Bladder genetic test available in the UK for the first time. Lydia Makaroff from Fight Bladder Cancer commented on the news.

“A non-invasive test, used alongside cystoscopies, is something patients have been asking for; having one accurate enough to reduce the number of cystoscopies would represent a significant improvement for patients.”

Dr Lydia E Makaroff, Chief Executive at Fight Bladder Cancer

13/11/2023

Our Informed Genomics team is at the BAUS (The British Association of Urology Surgeons) Section of Oncology Meeting today and tomorrow in Manchester. Find us in the Barbirolli room inside the Bridgewater Hall.

After the exciting launch of our pioneering GALEAS™ Bladder testing service last week, and Bupa’s announcement to reimburse GALEAS™ Bladder, we will be discussing with Consultant Urologists the implementation of this service into clinical practice.

Last evening, we held an interactive speaker event at the King Street Townhouse where Rik Bryan, Andrew Feber, and Chidi Molokwu presented compelling information on the panel design, the clinical development program for the GALEAS Bladder service, along with how molecular biomarker tests such as this could be adopted routinely into clinical practice.

The feedback has been very positive with great discussions between our attendees and speakers as to the adoption of the test for patients with haematuria.

You can also follow this link to read our press release about our partnership with who will be offering the GALEAS™ Bladder service to their eligible members: https://bit.ly/4793QgN



Bupa UK to reimburse GALEAS™ Bladder for individuals at risk of bladder cancer -
Informed Genomics Limited and Bupa insurance have collaborated to make a pioneering genetic test for bladder cancer available for the first time in the UK.

20/10/2023

🎗️ October is ! 🎗️

According to Cancer Research UK, over 55,000 new cases of breast cancer are diagnosed each year, making it the most common cancer among women.

Today is Wear it Pink day to raise awareness for the fight against breast cancer, so our staff, in the office and online, are wearing it pink!👚

Informed Genomics provides a breast cancer hereditary gene panel to the NHS, and private sector clinicians to identify individuals with a genetic pre-disposition to breast cancer. These panels may also be covered by your private medical insurance. We are driven to provide accessible genomic testing, to enable an earlier diagnosis and more personalised treatment pathway.

If you would like to learn more about this test follow this link: https://bit.ly/408gD03 or speak to your clinician about our service.

Breast cancer affects millions of lives, and early detection can make all the difference.
Share this post to raise awareness, and encourage your loved ones to schedule their screenings.

Together, we can make a real impact!

10/10/2023

Our market research feedback demonstrates that 59.7% of our customers use our NGS translational genomics services and 29.8% use our sample-to-report clinical services.

Building on this, the 3 most important qualities cited by our customers when choosing Informed Genomics as their outsource partner for genomic services were:

1. Quality and reliability of results
2. Turnaround time (TAT)
3. Price

Our portfolio includes genomics services such as:

• Whole Exome Sequencing (34%)
• Whole Genome Sequencing (10%)
• Custom Panel Design & Sequencing (22%)

From our responders interested in translational genomics, 70% of them have subscribed to be notified when we launch our new RNA sequencing service! On the clinical side, 66.6% have subscribed to be notified when we launch our urine sample-to-report GALEASᵀᴹ/ Bladder service.

One of our responders had some amazing words:

“Overall very pleased with the service from Informed Genomics. Communication was excellent and made everything much easier than dealing with other sequencing companies. Data turnaround time was very quick once all samples were sent off.”

Follow us to stay updated on our upcoming service launches and click the link to view our portfolio of translational genomics services: https://bit.ly/46lhgpm

06/10/2023

Say hello to Ryan! 👋

Ryan is our Senior Lab Technician and is a part of our phenomenal lab team who make sure that all the lab work conducted on your samples is performed with exceptional quality. So, we wanted to ask him what is his favourite part about working in the lab and being a part of the team?

27/08/2023

To celebrate our successful UKAS extension to scope that was completed with no findings being raised, the team headed out for a fun night playing laser tag and enjoying a tasty curry 🤩

25/08/2023

Here is what one of customers had to say about our sequencing services.

We are very grateful for the kind words from Kasia at CoSyne Therapeutics has said about us. This motivates us to keep up the hard work and make sure we deliver outstanding quality for our customers!

Browse our range of translational genomic services on our website: https://bit.ly/3P96e0v

To enquire and speak to a member of our team, please do send an email to [email protected]

23/08/2023

At Informed Genomics, our mission is more than just words; it's the driving force behind everything we do. All our operations that are carried out and partnerships that we aim to develop is to be able to provide accessible and personalised cancer treatments to improve patient outcomes.

We make sure to live our values in the way we work as a team and how we aim to help our customers; making sure to convey our passion and integrity in our work, and to deliver our services with the best of quality.